Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.

NPJ Breast Cancer · 2021 · PMC8052445 · PMID 33863913

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significanceP = 0.15not close (p > 0.1)

Three of the four cases with a partial response (PR) had a co-occurring PIK3CA mutation, but the association of co-occurring PIK3CA mutations with PFS did not reach statistical significance ( P = 0.15) in this small cohort.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.